TONELLO, MARTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.513
AS - Asia 374
EU - Europa 260
OC - Oceania 1
Totale 3.148
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.506
CN - Cina 183
SG - Singapore 146
IT - Italia 69
FI - Finlandia 47
DE - Germania 37
SE - Svezia 28
FR - Francia 25
GB - Regno Unito 25
JP - Giappone 21
VN - Vietnam 16
UA - Ucraina 10
CZ - Repubblica Ceca 6
MX - Messico 5
BE - Belgio 4
HK - Hong Kong 4
IN - India 4
NL - Olanda 3
RU - Federazione Russa 3
CA - Canada 2
IE - Irlanda 2
NZ - Nuova Zelanda 1
PT - Portogallo 1
Totale 3.148
Salva come PNG Salva come JPEG
Città #
Fairfield 433
Chandler 277
Woodbridge 232
Ashburn 213
Houston 187
Ann Arbor 153
Seattle 133
Cambridge 129
Wilmington 115
Singapore 114
Santa Clara 76
Boardman 58
San Diego 49
Princeton 41
Des Moines 36
Medford 35
Beijing 34
Padova 34
Jacksonville 30
Roxbury 28
Helsinki 22
Nanjing 22
Dong Ket 16
Mito 10
Nanchang 10
New York 9
Tsukuba 9
Dearborn 8
Washington 8
Guangzhou 7
Brno 6
London 6
Zhengzhou 6
Hebei 5
Jinan 5
Milan 5
Allauch 4
Dallas 4
Falkenstein 4
Hefei 4
Hong Kong 4
Kunming 4
Shenyang 4
Brussels 3
Changsha 3
Frankfurt am Main 3
Kharkiv 3
Kilburn 3
Los Angeles 3
Ningbo 3
Norwalk 3
Ogden 3
Rome 3
Auburn Hills 2
Bussero 2
Castelfranco Emilia 2
Chongqing 2
Dongguan 2
Dublin 2
Florence 2
Hanover 2
Harbin 2
Herndon 2
Jiaxing 2
Nürnberg 2
Ponte di Piave 2
Prescot 2
Redwood City 2
Serrenti 2
Taiyuan 2
Acton 1
Arezzo 1
Arzignano 1
Auckland 1
Castello di Godego 1
Cerea 1
Changchun 1
Chiswick 1
Fenghua 1
Fuzhou 1
Haikou 1
Hangzhou 1
Hounslow 1
Huzhou 1
Indiana 1
Lappeenranta 1
Leicester 1
Lisbon 1
Mandi 1
Montreal 1
Nanning 1
Orange 1
Pune 1
Quzhou 1
Shanghai 1
Taizhou 1
Toronto 1
Wandsworth 1
Xian 1
Totale 2.682
Salva come PNG Salva come JPEG
Nome #
Plasma exchange effectively removes 52- and 60-kDa anti-Ro/SSA and anti-La/SSB antibodies in pregnant women with congenital heart block. 142
Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report 115
Increased apoptosis in circulating lymphocyte cultures of anti-RNA polymerase III positive patients with systemic sclerosis. 114
Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review 111
Prognosis of scleroderma renal crisis: a long-term observational study. 107
Hypertension negatively affects the pregnancy outcome in patients with antiphospholipid syndrome. 106
Clinical and laboratory characteristics of isolated lupus anticoagulants 106
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles 106
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein i antibodies. A comparison with a homemade ELISA method 104
Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. 101
The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome 97
Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile 93
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk 91
Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study 91
Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. 90
Low titer, isolated anti Ro/SSA 60 kd antibodies is correlated with positive pregnancy outcomes in women at risk of congenital heart block 88
Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study 84
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. 81
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome 80
Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. 78
Maternal autoantibody profiles at risk for autoimmune congenital heart block: a prospective study in high-risk patients 76
Clinical value of anti-domain I-β2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study 73
Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome 72
Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. 72
Risk-based secondary prevention of obstetric antiphospholipid syndrome. 71
[Clinical significance of fluoroscopic patterns specific for the mitotic spindle in patients with rheumatic diseases]. 70
Unstabilized DNA breaks in lymphocytes of patients with different subsets of systemic sclerosis 66
Antiphosphatidylserine/prothrombin antibodies in antiphospholipid syndrome with intrauterine growth restriction and preeclampsia 66
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 64
Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study 64
Detection of autoantibodies to the p200-epitope of SSA/Ro52 antigen. A comparison of two laboratory assays 63
IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. 59
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 57
The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies. 51
Unstabilized DNA breaks in lymphocytes of patients with systemic sclerosis. 47
IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis 45
Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases 43
Impact of COVID-19 and COVID-19 vaccination on high-risk patients with Antiphospholipid Syndrome: a nationwide survey 33
High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets 23
High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets 23
Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome 19
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies 19
Risk factors for damage accrual in primary antiphospholipid syndrome: A retrospective single-center cohort study 13
Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity? 12
Prevalence and adverse consequences of delayed diagnosis and misdiagnosis in thrombotic antiphospholipid syndrome. An observational cohort study and a review of the literature 11
Prevalence and adverse consequences of delayed diagnosis and misdiagnosis in thrombotic antiphospholipid syndrome. An observational cohort study and a review of the literature 4
Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome 1
Totale 3.202
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.541
article - articoli 14.541
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.082
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020369 0 0 0 0 0 43 82 69 65 45 25 40
2020/2021368 18 62 6 34 7 21 12 43 51 22 60 32
2021/2022579 22 54 87 38 20 36 24 61 27 12 47 151
2022/2023462 103 72 4 63 63 57 7 35 33 5 18 2
2023/2024324 13 53 41 26 22 51 26 14 13 5 25 35
2024/2025347 4 62 52 51 122 56 0 0 0 0 0 0
Totale 3.202